SI-BONE (NASDAQ:SIBN) Trading Down 4.5% – What’s Next?

Shares of SI-BONE, Inc. (NASDAQ:SIBN) fell 4.5% during mid-day trading on Monday . The stock traded as low as $12.81 and last traded at $12.77. 38,819 shares changed hands during trading, a decline of 89% from the average session volume of 362,545 shares. The stock had previously closed at $13.37.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a report on Tuesday, February 25th. Needham & Company LLC lifted their price target on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, Truist Financial reissued a “buy” rating and issued a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $24.40.

SI-BONE Trading Down 2.3 %

The firm’s fifty day moving average price is $15.47 and its 200-day moving average price is $14.63. The company has a market cap of $554.01 million, a price-to-earnings ratio of -14.18 and a beta of 1.02. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. On average, equities analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Anthony J. Recupero sold 3,311 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now directly owns 284,555 shares of the company’s stock, valued at approximately $4,026,453.25. This represents a 1.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the transaction, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. This represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,776 shares of company stock worth $96,644. 3.90% of the stock is owned by company insiders.

Institutional Trading of SI-BONE

Institutional investors have recently modified their holdings of the company. FMR LLC grew its holdings in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the period. Virtus Fund Advisers LLC acquired a new position in shares of SI-BONE in the 4th quarter worth approximately $40,000. Mainstream Capital Management LLC bought a new stake in shares of SI-BONE in the 4th quarter worth approximately $53,000. GAMMA Investing LLC lifted its stake in SI-BONE by 20,352.6% during the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock valued at $55,000 after purchasing an additional 3,867 shares during the last quarter. Finally, R Squared Ltd bought a new stake in SI-BONE during the fourth quarter worth approximately $73,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.